Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Int J Med Inform. 2019 Apr 13;127:27–34. doi: 10.1016/j.ijmedinf.2019.04.009

Table 6.

Total number of Tdap-related local reaction cases identified and estimated incidence rates for three different methods of case ascertainment.

Site Study population With codes a Median age of patients with codes With codes & notes b Code-based incidence rate c NLP positive d NLP-based incidence rate c
KPSC 1,240,594 5271 42.9 5268 42.5 1770 14.3
KP site 2 151,998 486 45.5 483 32.0 162 10.7
KP site 3 158,574 489 52.1 489 30.8 145 9.1
Non-KP site 1 281,903 768 55.9 626 27.2 150 5.3
Non-KP site 2 71,526 301 54.6 257 42.1 40 5.6
Overall 1,904,595 7315 NA 7123 38.4 2267 11.9
a

Number of patients identified using ICD-9-CM local reaction codes documented in all care settings in the 1–6 days following vaccination with Tdap.

b

For the patients identified by ICD-9-CM codes, number of patients who had at least one chart note available for NLP in the 1–6 days after vaccination.

c

Incidence rates represent the number of identified cases per 10,000 Tdap vaccinees as defined in the “Study population” column.

d

Number of positive cases identified by NLP among patients with ICD-9-CM codes in the 1–6 days following vaccination with Tdap.